Approved Agents and Related Trials

摘要

For years, docetaxel was the only therapeutic option that was proven to have a favorable effect on survival outcomes for men with metastatic castration-resistant prostate cancer (mCRPC), improving overall survival (OS) by 2.4 months. Previously, other options were palliative, but this has changed. Sipuleucel-T, cabazitaxel, and abi-raterone are now also approved for use in mCRPC by the U.S. Food and Drug Administration (FDA) following positive phase III trials. Additional options are anticipated, including radium-223 (Table 1). Further, denosumab expands options for bone health and to delay progression of bone disease in men with MO CRPC.